Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition

Eye drug maker Tarsus Pharmaceuticals said on Thursday it would acquire privately held Alkeus Pharmaceuticals in a cash-and-stock deal worth ​up to $800 million, adding an experimental oral therapy fo...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。